Amgen Inc. $AMGN Shares Purchased by Canada Pension Plan Investment Board

Canada Pension Plan Investment Board increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 39.7% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 963,209 shares of the medical research company’s stock after purchasing an additional 273,719 shares during the period. Canada Pension Plan Investment Board’s holdings in Amgen were worth $348,797,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Dogwood Wealth Management LLC raised its holdings in shares of Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after buying an additional 55 shares during the period. Anfield Capital Management LLC grew its position in Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 70 shares in the last quarter. Tower View Wealth Management LLC increased its stake in Amgen by 331.6% during the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after purchasing an additional 63 shares during the period. Manning & Napier Advisors LLC increased its stake in Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after purchasing an additional 32 shares during the period. Finally, Ares Financial Consulting LLC acquired a new stake in shares of Amgen during the fourth quarter worth about $34,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Transactions at Amgen

In other news, SVP Rachna Khosla sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total transaction of $825,140.00. Following the completion of the sale, the senior vice president owned 6,404 shares in the company, valued at approximately $2,642,098.28. The trade was a 23.80% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the sale, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 6,222 shares of company stock worth $2,540,926. Company insiders own 0.85% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on AMGN. Daiwa Securities Group dropped their price objective on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a report on Wednesday, May 13th. Royal Bank Of Canada increased their target price on shares of Amgen from $370.00 to $400.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. Robert W. Baird raised their price target on shares of Amgen from $215.00 to $230.00 and gave the company an “underperform” rating in a research report on Wednesday, August 5th. Argus boosted their price target on shares of Amgen from $375.00 to $460.00 and gave the stock a “buy” rating in a research note on Wednesday, August 19th. Finally, Wells Fargo & Company upped their price objective on Amgen from $390.00 to $400.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have assigned a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $380.43.

Amgen Stock Down 0.4%

AMGN stock opened at $442.24 on Wednesday. The company’s 50 day moving average price is $382.78 and its 200 day moving average price is $363.35. The firm has a market capitalization of $239.09 billion, a price-to-earnings ratio of 27.49, a PEG ratio of 3.20 and a beta of 0.41. Amgen Inc. has a fifty-two week low of $269.77 and a fifty-two week high of $447.03. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.62 by $0.67. The business had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same period in the previous year, the company earned $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities research analysts anticipate that Amgen Inc. will post 22.92 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s dividend payout ratio is currently 62.65%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.